ES2669528T3 - Receptor Tie2 específico de angiopoyetina-2 - Google Patents

Receptor Tie2 específico de angiopoyetina-2 Download PDF

Info

Publication number
ES2669528T3
ES2669528T3 ES13815108.9T ES13815108T ES2669528T3 ES 2669528 T3 ES2669528 T3 ES 2669528T3 ES 13815108 T ES13815108 T ES 13815108T ES 2669528 T3 ES2669528 T3 ES 2669528T3
Authority
ES
Spain
Prior art keywords
angiopoietin
tie2 receptor
specific tie2
receptor
polypeptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES13815108.9T
Other languages
English (en)
Inventor
Nicolas Phillip James BRINDLE
Julian Edward Sale
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Medical Research Council
Original Assignee
Medical Research Council
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medical Research Council filed Critical Medical Research Council
Application granted granted Critical
Publication of ES2669528T3 publication Critical patent/ES2669528T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/10—Protein-tyrosine kinases (2.7.10)
    • C12Y207/10001—Receptor protein-tyrosine kinase (2.7.10.1)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Communicable Diseases (AREA)

Abstract

Un polipéptido que comprende un receptor de angiopoyetina modificado o fragmento del mismo, en el que el polipéptido se une preferentemente a angiopoyetina-2 en comparación con angiopoyetina-1; en el que el receptor de angiopoyetina es Tie2, y en el que el 5 polipéptido comprende la siguientes mutaciones con respecto a la SEQ ID NO: 1 o SEQ ID NO: 2: (i) F161I, ΔR167 y ΔH168, o (ii) F161G, ΔR167 y ΔH168.
ES13815108.9T 2012-12-20 2013-12-20 Receptor Tie2 específico de angiopoyetina-2 Active ES2669528T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1223053.8A GB201223053D0 (en) 2012-12-20 2012-12-20 Receptor
GB201223053 2012-12-20
PCT/GB2013/053392 WO2014096855A1 (en) 2012-12-20 2013-12-20 Angiopoietin-2 specific tie2 receptor

Publications (1)

Publication Number Publication Date
ES2669528T3 true ES2669528T3 (es) 2018-05-28

Family

ID=47682309

Family Applications (1)

Application Number Title Priority Date Filing Date
ES13815108.9T Active ES2669528T3 (es) 2012-12-20 2013-12-20 Receptor Tie2 específico de angiopoyetina-2

Country Status (10)

Country Link
US (2) US10208100B2 (es)
EP (1) EP2935322B1 (es)
JP (2) JP6466852B2 (es)
CN (1) CN105143256B (es)
AU (1) AU2013366050B2 (es)
CA (1) CA2895645A1 (es)
DK (1) DK2935322T3 (es)
ES (1) ES2669528T3 (es)
GB (1) GB201223053D0 (es)
WO (1) WO2014096855A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3250586B1 (en) 2015-01-28 2021-10-27 Pieris Pharmaceuticals GmbH Novel proteins specific for angiogenesis
CN106994185B (zh) * 2016-01-22 2021-04-06 何玉龙 Tie2对视网膜及其他组织中静脉血管的保护作用及应用
CN115947818B (zh) * 2022-10-25 2024-08-02 福州大学 一种血管生成素1突变体的设计及其制备方法和应用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
US5147638A (en) 1988-12-30 1992-09-15 Oklahoma Medical Research Foundation Inhibition of tumor growth by blockade of the protein C system
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US7122339B2 (en) 1998-10-09 2006-10-17 Medical Research Council Method for generating diversity
CA2675802A1 (en) 1998-10-09 2000-04-20 Medical Research Council Use of an immunoglobulin-producing cell line to gererate diversity in a gene or gene product
DK1187918T4 (da) 1999-06-07 2009-02-23 Immunex Corp TEK-antagonister
US6521424B2 (en) * 1999-06-07 2003-02-18 Immunex Corporation Recombinant expression of Tek antagonists
AU2002314433A1 (en) 2001-07-02 2003-01-21 Licentia Ltd. Ephrin-tie receptor materials and methods
DK1506288T3 (da) 2002-05-10 2013-07-22 Medical Res Council Aktiveringsinduceret deaminase (aid)
EP1778264A2 (en) * 2004-06-25 2007-05-02 Licentia, Ltd. Tie receptor and tie ligand materials and methods for modulating female fertility
US10259860B2 (en) * 2007-02-27 2019-04-16 Aprogen Inc. Fusion proteins binding to VEGF and angiopoietin
WO2009158432A2 (en) * 2008-06-27 2009-12-30 Amgen Inc. Ang-2 inhibition to treat multiple sclerosis
JO3182B1 (ar) 2009-07-29 2018-03-08 Regeneron Pharma مضادات حيوية بشرية عالية الالفة مع تولد الاوعية البشرية - 2

Also Published As

Publication number Publication date
DK2935322T3 (en) 2018-07-16
US10208100B2 (en) 2019-02-19
JP6466852B2 (ja) 2019-02-06
EP2935322B1 (en) 2018-03-28
CN105143256A (zh) 2015-12-09
CN105143256B (zh) 2020-12-29
US20190218273A1 (en) 2019-07-18
AU2013366050B2 (en) 2018-04-26
US20150322414A1 (en) 2015-11-12
US10882895B2 (en) 2021-01-05
AU2013366050A1 (en) 2015-07-30
JP2016503050A (ja) 2016-02-01
CA2895645A1 (en) 2014-06-26
EP2935322A1 (en) 2015-10-28
GB201223053D0 (en) 2013-02-06
WO2014096855A1 (en) 2014-06-26
JP2019088293A (ja) 2019-06-13

Similar Documents

Publication Publication Date Title
BR112013032717A2 (pt) coagonistas do receptor de glucagon/glp-1
MX2015012553A (es) Variantes de fc.
CY1120413T1 (el) Ειδικα εξανθρωπισμενα αντισωματα στην πρωτοϊνιδιακη μορφη του βητα-αμυλοειδους πεπτιδιου
HRP20181741T1 (hr) Postupci proizvodnje za kontrolu sadržaja c-terminalnog lizina, galaktoze i sijalinske kiseline u rekombiniranim proteinima
MX2020010399A (es) 3-epimerasa.
MX2021009634A (es) Transferencia de genes al sistema nervioso central mediada por virus adeno-asociados.
UA111818C2 (uk) Антитіло проти csf-1r
NI201300143A (es) Coagonista del receptor de glucagón/glp-1
CR20150039A (es) Caucho natural que contiene nanocarbono
NZ761188A (en) Antibody molecules to tim-3 and uses thereof
BR112014019901A2 (pt) proteínas de fator viii recombinante
NZ628446A (en) Fibronectin based scaffold domain proteins that bind to myostatin
UY33983A (es) Proteínas de Unión de Tipo Anticuerpo con Región Variable Dual que Tienen Orientación de la Región de Unión con Entrecruzamiento.
BR112015021269A2 (pt) peptídeos e composições para tratamento de dano articular
EA201590994A1 (ru) Способ увеличения гидродинамического объема полипептида путем присоединения карбоксиконцевого пептида гонадотропина
MX359315B (es) Vacuna de adn para usarse en pacientes con cancer pancreatico.
JO3026B1 (ar) مستضادات ببتيد شبيه الجلوكاجون - 2
EA201300876A1 (ru) Мутантная целлобиогидролаза
EA201291065A1 (ru) Антитела против vla-4
BR112015008824A2 (pt) linhagens melhoradas de microalgas e processo das mesmas
EA201500422A1 (ru) Композит, армированный волокнами
ES2669528T3 (es) Receptor Tie2 específico de angiopoyetina-2
BR112017006536A2 (pt) polipeptídeo de ligação ao anticorpo, polipeptídeo de fusão de ligação ao anticorpo, e material de adsorção
ES2526109R2 (es) Péptido y composición farmacéutica para el tratamiento del cáncer
CO7051011A2 (es) Anticuerpos recombinantes con especificidad dual por gangliósidos y su uso